PUREGON

Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha.

• and beta.

The alpha.

• subunits have and 111 amino acids.

The alpha subunit is glycosylated at Asn and Asn 78 while the beta subunit is glycosylated at Asn and Asn 24.

Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO).

The nomenclature “beta” differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha.

Follitropin is important in the development of follicles produced by the ovaries.

Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.

Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).

Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable.

However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.

Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH).

Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH.

However, these small differences do not affect the bioactivity compared to natural FSH.

In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.

In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis.

Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).

Used for the treatment of female infertility, Follitropin beta or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure.

FSH, the active component of Follitropin beta is the primary hormone responsible for follicular recruitment and development.

The absorption rate is the main driving force behind the pharmokinetics of Follitropin alpha as the rate of absorption was found to be slower than the elimination rate after administration Subcutaneous and Intramuscular.

The bioavailability is approximately 66-76%.

The time to peak after subcutaneous injection in healthy volunteers was 8-16 hours in females and 11-20 hours in males.

Via liver and kidneys.

Circulation half life of 3-4 hours, elimination half life of 35-40 hours.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.

Headaches, ovarian cysts, nausea and upper respiratory tract infections occurred in more than 10% of women in clinical trials.

In men, the most serious adverse events reported were testicular surgery for cryptorchidism which existed prestudy, hemoptysis, an infected pilonidal cyst, and lymphadenopathy associated with an Epstein-Barr viral infection.

Other concerns include overstimulation of the ovaries, pulmonary and vascular complications and multiple births.

Post-marketing reports revealed hypersensitivity reactions including anaphylactoid reactions and asthma.

Follitropin is contraindicated in pregnant women.

No studies have been done in nursing mothers.